Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Vyalev a continuous subcutaneousinfusion for Parkinson’s disease is now launched in Japan – AbbVie

Written by | 1 Aug 2023 | Neurology

AbbVie has launched Vyalev (foslevodopa + foscarbidopa), a continuous subcutaneous infusion for Parkinson’s disease, in Japan on July 26. This is the first Parkinson’s drug in the country that can be continuously infused for 24 hours without requiring surgery.

In Japan, Vyalev was approved in December 2022 for the improvement of wearing-off symptoms in Parkinson’s inadequately controlled with existing pharmacotherapies including levodopa-containing preparations. Peak sales are projected at 9.6 billion yen in the 10th year, according to data presented to the Central Social Insurance Medical Council (Chuikyo).

The current standard of care for Parkinson’s is levodopa/carbidopa therapy. As symptoms progress, patients need to receive frequent administrations, and if the disease further advances and becomes difficult to control, the primary treatment option has traditionally been device-aided therapies that require surgery, such as levodopa-carbidopa intestinal gel (LCIG) therapy that involves creating a gastrostomy. If Vyalev is used in these cases, surgery can be avoided, reducing the burdens on patients and meeting the unmet needs in the treatment of advance Parkinson’s disease.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.